ENYO Pharma is a late-stage clinical-stage biopharmaceutical company founded in 2014. Its mission is to develop innovative renal therapies to treat patients with kidney failure to prevent end-stage renal disease, dialysis and kidney transplantation. Among renal indications, chronic kidney disease (CKD) is recognized as a global public health problem because it affects 850 million people worldwide and will become the fifth cause of death by 2040. There is no cure for CKD. The current treatments mainly consist of marketed drugs dedicated to other indications (anti-hypertensives, diuretics, anti-diabetics drugs) with limited outcomes. To address the critical problem of these underserved CKD patients, ENYO Pharma is currently developing a pipeline of drugs with unique curative potential that is expected to fundamentally change the management of CKD indications. From a small synthetic molecule, Vonafexor, the company has created a family of molecules with several analogues exhibiting new and unique properties. Based on robust data obtained with Vonafexor in nine completed Phase 1/2 clinical studies in over 300 subjects, ENYO Pharma is focused on the development of its innovative new once-daily oral medication, Vonafexor-Lys. Vonafexor-Lys is the company value driver. The STOP-CKD project “Strong Therapeutic Opportunity To Protect From Chronic Kidney Disease” will accelerate the clinical validation of Vonafexor-Lys in a leading European nephrology center. By the end of 2025, we will have achieved the industrialization of the drug product and carried out three decisive renal clinical studies in Europe. This will enable product registration by 2029-2030. The EIC accelerator will be a fantastic booster for Vonafexor's pipeline for major kidney diseases. This will also support ENYO Pharma to continue its development in other critical diseases related to kidney impairment.